CARLSBAD, Calif., April 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize.
Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009, in San Antonio, TX, for work published in the Journal of Pharmaceutical Sciences entitled "Oral Delivery of Antisense Oligonucleotides in Man." His co-authors are Richard S. Geary, Ph.D. and Gregory E. Hardee, Ph.D. (1)
I would like to recognize my co-authors, whose advice and hard work contributed significantly to this publication," said Lloyd Tillman
"Our work demonstrated, for the first time, that antisense drugs could be administered orally.
The feasibility of oral administration has dramatically broadened the therapeutic and commercial potential of antisense drugs."
The research, which was published in January 2008, provided proof-of-concept for the oral administration of antisense drugs in a single-dose study in man. Scientists at Isis
continue to research advances to enhance the pharmaceutical properties of antisense drugs, including oral bioavailability.
"We are pleased that Dr. Tillman
was recognized by the APhA
to receive this award on our seminal work in advancing the oral delivery of antisense drugs.
(1) Lloyd Tillman
, Richard S. Geary, Gregory E. Hardee.